prostate cancer (mHSPC)
Oncology · 2016–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| abiraterone acetate and methylprednisolone Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. | Jul 2023 | Recommended | input received Medical Oncology Group |
| darolutamide Treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) and docetaxel. | May 2023 | Deferred | 21 individuals Prostate Cancer Foundation · Geelong Prostate Support Group · Medical Oncology Group |
| enzalutamide Treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC), irrespective of disease volume or suitability for docetaxel. | Mar 2023 | Recommended with restriction | input received Medical Oncology Group |
| apalutamide Metastatic hormone-sensitive prostate cancer (mHSPC) in patients with low-volume disease or high-volume disease unsuitable for docetaxel, used in combination… | Jul 2022 | Recommended with restriction | 21 individuals Prostate Cancer Foundation · Bathurst District Prostate Cancer Support Group · Support Group · South Eastern Prostate Cancer Support Group · Wagga Wagga Prostate Cancer Support Group · Westmead Prostate Cancer Support Group · Blue Mountains Prostate Cancer Support Group · Latrobe Valley Prostate Support Group · Medical Oncology Group · Society for Medical Oncology Magnitude of Clinical Benefit |
| apalutamide Treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who have low volume disease or high volume disease who are unsuitable for… | Nov 2021 | Not recommended | 29 individuals Prostate Cancer Foundation · Medical Oncology Group |
| leuprorelin and bicalutamide Treatment of metastatic (Stage D) carcinoma of the prostate in patients requiring a combination of an antiandrogen and a GnRH (LH-RH) agonist. | Jul 2016 | Recommended with restriction | none received |
Who spoke
Medical Oncology Group · Prostate Cancer Foundation · Bathurst District Prostate Cancer Support Group · Support Group · South Eastern Prostate Cancer Support Group · Wagga Wagga Prostate Cancer Support Group · Westmead Prostate Cancer Support Group · Blue Mountains Prostate Cancer Support Group · Latrobe Valley Prostate Support Group · Society for Medical Oncology Magnitude of Clinical Benefit · Geelong Prostate Support Group
What the PBS pays
$483M in government benefit over 2024–25, across 895,908 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| enzalutamide | $179.9M |
| darolutamide | $147.6M |
| leuprorelin and bicalutamide | $58.1M |
| apalutamide | $50.6M |
| abiraterone acetate and methylprednisolone | $46.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 9 technologies for this condition, recommending 9 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| talazoparibTalazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer | TA1130 | recommended | 2026-02 |
| abirateroneAbiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer | TA1110 | recommended | 2025-11 |
| darolutamideDarolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA1109 | recommended restricted | 2025-11 |
| relugolixRelugolix for treating hormone-sensitive prostate cancer | TA995 | recommended | 2024-08 |
| olaparibOlaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | recommended restricted | 2024-02 |
| darolutamideDarolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | recommended restricted | 2023-06 |
| apalutamideApalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | recommended restricted | 2021-10 |
| enzalutamideEnzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | recommended restricted | 2021-07 |
| degarelixDegarelix for treating advanced hormone-dependent prostate cancer | TA404 | recommended restricted | 2016-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.